archive-org.com » ORG » M » MATWIN.ORG

Total: 320

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • MATWIN - mentions légales
    les dates et heures de l intervention Le site www matwin org est mis à jour régulièrement par l équipe MATWIN De la même façon les mentions légales peuvent être modifiées à tout moment elles s imposent néanmoins à l utilisateur qui est invité à s y référer le plus souvent possible afin d en prendre connaissance POLITIQUE DE CONFIDENTIALITE UTILISATION DES COOKIES Lors de la consultation de notre site internet www matwin org des informations sont susceptibles d être enregistrées dans des fichiers Cookies installés dans votre ordinateur tablette téléphone mobile ou tout autre appareil optimisé pour Internet Qu est ce qu un cookie Les Cookies sont des fichiers de taille réduite qui sont envoyés vers votre navigateur lors de la consultation d un contenu Ils sont stockés dans un espace dédié du disque dur de votre terminal ordinateur tablette téléphone mobile ou tout autre appareil optimisé pour Internet Le stockage des cookies répond à plusieurs finalités Les cookies de fonctionnement permettent de vous proposer une navigation de qualité Les cookies de mesure d audience nous permettent d améliorer progressivement notre site internet et les informations que nous vous proposons Les cookies de réseaux sociaux vous permettent de partager du contenu sur différents réseaux comme Twitter LinkedIn etc Comment puis je désactiver les cookies La plupart des navigateurs acceptent automatiquement les cookies mais vous pouvez également décider de ne pas les accepter Il est conseillé de ne pas désactiver cette fonction Cela pourrait altérer le bon fonctionnement de votre navigation sur le site Si vous ne souhaitez pas que votre ordinateur reçoive et mémorise les cookies vous pouvez configurer manuellement votre navigateur et en modifier les paramètres de sécurité Pour modifier vos paramètres de confidentialité et bloquer le dépôt de cookies il vous faut accéder aux configurations de votre

    Original URL path: http://www.matwin.org/mentions-legales.html (2016-02-11)
    Open archived version from archive

  • Plan du site
    organizing on June 30th and July 1st 2016 Read more Subscribe to SITE MAP MATWIN Presentation Staff Actors involved Committees Industrial partners Institutional partners Canceropoles and institutions partners Programme Programme process Submit your project Technology offers MEET2WIN 2016 Programme and registration Useful information Sponsorship opportunities Zoom on Call for proposal MATWIN MATWIN went to BioFit RIA MATWIN 1st assessment Pierre Fabre new programme partner BAYER HEALTHCARE new MATWIN partner Tribute

    Original URL path: http://www.matwin.org/plan-du-site.html (2016-02-11)
    Open archived version from archive

  • Cancéropoles and institutions partners
    organize in Bordeaux next May 12th and 13th 2016 the 2nd edition of Read more Subscribe to Coming next AGENDA Cancéropôle PACA annual congress June 30th July 1st 2016 The Cancéropôle PACA is organizing on June 30th and July 1st 2016 Read more Subscribe to Canceropoles and institutions partners Canceropole Grand Est Learn more Canceropole Grand Ouest Learn more Canceropole Grand Sud Ouest Learn more Canceropole Nord Ouest Learn more

    Original URL path: http://www.matwin.org/acteurs/partenaires_institutionnels-p22.html (2016-02-11)
    Open archived version from archive

  • MATWIN - Maturation & Accelerating Translation With Industry
    Oncology Business convention MEET2WIN 2016 MATWIN will organize in Bordeaux next May 12th and 13th 2016 the 2nd edition of Read more Subscribe to Coming next AGENDA Cancéropôle PACA annual congress June 30th July 1st 2016 The Cancéropôle PACA is organizing on June 30th and July 1st 2016 Read more Subscribe to Result s No matching results were found MEDIA CENTRE Legal notices Site Map Contact With the support of

    Original URL path: http://www.matwin.org/les-resultats-de-votre-recherche.html (2016-02-11)
    Open archived version from archive

  • MATWIN Team
    organizing on June 30th and July 1st 2016 Read more Subscribe to Staff Josy Reiffers President Josy Reiffers is hematologist Since 2005 he is head of Institut Bergonié regional center for cancer treatment in Bordeaux Since 2010 he is also president of UNICANCER a hospital group entirely devoted to fighting cancer As he was Great South West Canceropole CEO from 2009 to 2011 he initiated MATWIN Learn more Lucia Robert CEO Before joining MATWIN in 2011 Lucia shared her experience on Innovation Transfer with the Bordeaux City Hall Alain Juppé working as a Project manager on Innovation and Higher education within the Economic Development direction Prior to the Bordeaux City hall Lucia has held various positions dealing with Technology Transfer Learn more Cécile Faurie Project manager Cécile Faurie is PhD in celullar biophysics Previously she was the coordination manager of the Centre de Référence des Pathologies Plaquettaires Reference Center for Platelet Disorders at Bordeaux University Hospital Then in 2009 she joined the Cancéropole Grand Sud Ouest as Scientific Assistant Officer of the Learn more Stephanie Dhont Management assistant With a Bachelor of business administration degree Stéphanie Dhont improved her foreign languages skills through various long stays abroad England Mexico United

    Original URL path: http://www.matwin.org/matwin/staff-p9.html (2016-02-11)
    Open archived version from archive

  • MATWIN : pharmaceuticals companies have been involved in the construction of the programme
    in the Americas and 26 5 in Asia Pacific Learn more Bayer Healthcare Bayer HealthCare a subsidiary of Bayer AG is one of the world s leading innovative companies in the healthcare and medical products industry With the goal of improving the lives of people affected by cancer oncology research at Bayer is working on developing new cancer treatments and making them available to Learn more Bristol Myers Squibb As a global BioPharma leader Bristol Myers Squibb uniquely combines the reach and resources of a major pharmaceutical company with the can do spirit and agility of an innovative biotech The guiding principles and values behind our business strategy are expressed in the company s Mission to discover develop and deliver innovative medicines Learn more Celgene Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide At Celgene we seek to deliver truly innovative and life changing drugs for our patients Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery the development and the commercialization Learn more GlaxoSmithKline GlaxoSmithKline is a science led global healthcare company that researches and develops a broad range of innovative medicines and brands The company has three primary areas of business in pharmaceuticals vaccines and consumer healthcare Their success depends on creating innovative new products and making these accessible to as many people who need Learn more Janssen Janssen is a Johnson Johnson company which operates in three major fields Pharmacy with human medications as a main specialty in the group activity Consumer healthcare intended for a general public And eventually medical devices and diagnostics Janssen is developing treatments for patients in five important therapeutic areas Learn more Novartis Novartis provides healthcare solutions that address the evolving needs of patients and societies Focused

    Original URL path: http://www.matwin.org/actors_involved/industrial_partners-p12.html (2016-02-11)
    Open archived version from archive

  • MATWIN institutionnal partner
    2016 Read more Subscribe to Institutional partners INCa NCI INCa a National Health and Science Agency dedicated to Cancers The French National Cancer Institute was created by the Public Health Law of 9 August 2004 in the framework of the Cancer Plan 2003 2007 INCa is responsible for co ordinating activities in the fight against cancer in France and operates under Learn more UNICANCER group Both a shareholder and a

    Original URL path: http://www.matwin.org/actors_involved/institutional_partners-p23.html (2016-02-11)
    Open archived version from archive

  • Technology offers
    platinum responses in advanced lung cancer Lung cancer neurotensin immunotherapy cisplatin response Therapy pdf HERMOUET Sylvie Nantes University Multiplex infectious antigens micro arrays for personalized in vitro diagnosis of myeloma In Vitro Diagnostics IVD myeloma personalized medicine infection Diagnosis nc HUEBER Anne Odile Nice University Development of phosphorylated Fas based biomarker for apoptotic and survival outcome of Fas signaling in malignant haematological and solid tumours for improved design of targeted anti cancer therapies Targeted anti cancer Therapy biomarker tyrosine phosphorylation antibodies solid and liquid tumors apoptosis Diagnosis pdf PITTY Marc Henri OREGON Therapeutics Inhibitors of protein disulfide isomerase against cancer Oncology Resistance PDI Small Molecule Targeted Therapy First in Class Therapy pdf SALZET Michel Lille University GUIDED SURGERY OF CANCERS BY REAL TIME MASS SPECTROMETRY SPIDERMASS Real Time Monitoring Mass Spectrometry in vivo Diagnosis guided surgery Medical device Diagnosis pdf VANDIER Christophe Tours University Development of anti metastatic drugs inhibitors of SK3 based channel complex in targeted cancer therapy Anti metastatic drugs Potassium Channel Amphiphilic compound Ion channel inhibitor Therapy pdf WAGNER Alain Syndivia Bio Specific and bio Stable reagent for thiols ligation Cancer therapeutics Antibody Drug Conjugates Immunoconjugates breast cancer lymphoma Therapy pdf Projects that have reached the Board Audition in May 2014 Project leader name Organization Project name Keywords Classification Project sheet BARTHELEMY Philippe Bordeaux University Hybrid Nucleic Acid Lipids for Cancer Therapy nanomedicine drug delivery cancer chemotherapy Therapy pdf BRAUD Véronique Nice Molecular and cellular pharmacology Institute Development of therapeutic monoclonal antibodies for the treatment of B cell non Hodgkin s lymphomas Therapeutic antibodies cancer immunotherapy Therapy pdf DEHARO Eric Toulouse University SIMALIKALACTONE E A NEW NATURAL PRODUCT ACTIVE IN VIVO AGAINST DRUG RESISTANT HUMAN TUMORS MELANOMA LEUKEMIA AND OTHER MAPK DRIVEN CANCERS Simalikalactone MAPK driven cancers resistance B Raf V600E mutation Therapy pdf PACI Angelo Gustave

    Original URL path: http://www.matwin.org/programme/technology_offers-p18.html (2016-02-11)
    Open archived version from archive



  •